keyword
MENU ▼
Read by QxMD icon Read
search

Liver chemoembolization

keyword
https://www.readbyqxmd.com/read/29782618/liver-targeted-therapies-for-hepatocellular-carcinoma-prior-to-transplant-contemporary-management-strategies
#1
Mustafa Nazzal, Sameer Gadani, Abdullah Said, Mandy Rice, Obi Okoye, Ahmad Taha, Krista L Lentine
Hepatocellular carcinoma (HCC) is an aggressive neoplastic disease that has been rapidly increasing in incidence. It usually occurs in the background of liver disease, and cirrhosis. Definitive therapy requires surgical resection. However, in majority of cases surgical resection is not tolerated, especially in the presence of portal hypertension and cirrhosis. Orthotopic liver transplant (OLT) in well selected candidates has been accepted as a viable option. Due to a relative scarcity of donors compared to the number of listed recipients, long waiting times are anticipated...
April 2018: Global surgery
https://www.readbyqxmd.com/read/29779970/transarterial-chemoembolization-plus-iodine-125-implantation-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#2
REVIEW
Ze-Xin Zhu, Xiao-Xue Wang, Ke-Fei Yuan, Ji-Wei Huang, Yong Zeng
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common malignancy in liver. Transarterial chemoembolization (TACE) is recommended as an effective treatment in advanced HCC patients. Recent studies showed iodine-125 seed (a low-energy radionuclide) can provide long-term local control and increase survival for HCC patients. The aim of the study was to evaluate the outcome of TACE plus iodine-125 seed in comparison with TACE alone for HCC. METHODS: A comprehensive search of studies among PubMed, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews was conducted with published date from the earliest to January 10th, 2018...
May 17, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29774219/effect-and-safety-of-sorafenib-in-patients-with-intermediate-hepatocellular-carcinoma-who-received-transarterial-chemoembolization-a-retrospective-comparative-study
#3
Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu, Lin Wang
AIM: To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization (TACE) treatment for intermediate hepatocellular carcinoma (HCC). METHODS: Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B (BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone...
May 16, 2018: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/29765560/transarterial-chemoembolization-as-a-substitute-to-radiofrequency-ablation-for-treating-barcelona-clinic-liver-cancer-stage-0-a-hepatocellular-carcinoma
#4
Kentaro Ishikawa, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Sadahisa Ogasawara, Takahiro Maeda, Masayuki Yokoyama, Masanori Inoue, Toru Wakamatsu, Yuko Kusakabe, Tomoko Saito, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Fumio Imazeki, Naoya Kato
Background and Aim: Transarterial chemoembolization (TACE) is the standard procedure for treating Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC). However, it is often carried out in the treatment of BCLC stage 0/A HCC for various reasons. This study aimed to elucidate the prognosis for BCLC stage 0/A HCC patients treated with TACE or with radiofrequency ablation (RFA). Materials and Methods: The prognosis of 242 BCLC stage 0/A HCC patients within Milan criteria who underwent initially TACE or RFA were retrospectively analyzed using propensity score matching analysis...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29763951/dynamic-4d-ct-angiography-for-guiding-transarterial-chemoembolization-impact-on-the-reduction-of-contrast-material-operator-radiation-exposure-catheter-consumption-and-diagnostic-confidence
#5
Moritz H Albrecht, Thomas J Vogl, Julian L Wichmann, Simon S Martin, Jan-Erik Scholtz, Sebastian Fischer, Renate M Hammerstingl, Marc Harth, Nour-Eldin A Nour-Eldin, Axel Thalhammer, Stephan Zangos, Ralf W Bauer
PURPOSE:  This study was carried out to investigate the impact of abdominal dynamic four-dimensional CT angiography (4D-CTA) for guiding transarterial chemoembolization (TACE) on the amount of contrast material used, operator radiation exposure, catheter consumption, and diagnostic confidence. MATERIALS AND METHODS:  Written consent was waived for this IRB-approved retrospective study. 29 patients (20 men; mean age: 65.7 ± 11.5 years) with malignant liver lesions underwent 4D-CTA, prior to initial TACE...
June 2018: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://www.readbyqxmd.com/read/29752139/intraprocedural-parenchymal-blood-volume-is-a-predictor-of-treatment-response-for-chemoembolization-in-hepatocellular-carcinoma-results-of-a-prospective-study
#6
Nevin de Korompay, Mohammed Alshammari, Darren Klass, Frank Y Chou, John Chung, Stephen Ho, David M Liu
PURPOSE: To evaluate cone-beam parenchymal blood volume (PBV) before and after embolization as a predictor of radiographic response to transarterial chemoembolization in unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A phase IIa prospective clinical trial was conducted in patients with HCCs > 1.5 cm undergoing chemoembolization; 52 tumors in 40 patients with Barcelona Clinic Liver Criteria stage B disease met inclusion criteria. Pre- and postembolization PBV analysis was performed with a semiquantitative best-fit methodology for index tumors, with a predefined primary endpoint of radiographic response at 3 months...
May 8, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29743794/role-of-indocyanine-green-in-predicting-post-transarterial-chemoembolization-liver-failure-in-hepatocellular-carcinoma
#7
Shalimar, Sushil Jain, Shivanand R Gamanagatti, Saurabh Kedia, Bhaskar Thakur, Baibaswata Nayak, Harpreet Kaur, Deepak Gunjan, Shashi B Paul, Subrat K Acharya
Background/aim: Post-Transarterial Chemoembolization (TACE) Liver Failure (LF) is common in patients with Hepatocellular Carcinoma (HCC). No definitive objective parameters predict its occurrence. We assessed the role of Indocyanine Green (ICG) in prediction of post-TACE LF. Methods: Consecutive HCC patients with Child A/B class, categorized as Barcelona Clinic Liver Cancer (BCLC) staging A/B, were included between August 2012 and July 2014. All underwent ICG dynamics: Plasma Disappearance Rate (PDR) was recorded on the day of TACE...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29742715/liver-abscess-caused-by-clostridium-haemolyticum-infection-after-transarterial-chemoembolization-for-hepatocellular-carcinoma-a-case-report
#8
Dong-Jun Son, Ji-Yun Hong, Ki-Hyun Kim, Young-Hoon Jeong, Dae-Seong Myung, Sung-Bum Cho, Wan-Sik Lee, Yang-Jun Kang, Jin-Woong Kim, Young-Eun Joo
RATIONALE: Liver abscesses caused by Clostridium species infection are extremely rare. PATIENT CONCERNS: The authors report the first case of a liver abscess due to Clostridium haemolyticum, which occurred after transarterial chemoembolization (TACE) for hepatocellular carcinoma, in a 76-year-old woman who presented with right upper quadrant pain and fever. DIAGNOSES: Computed tomography of the abdomen after the second TACE showed an air-filled abscess around a compact, lipiodolized lesion in the right hepatic lobe...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29739489/safety-and-efficacy-analysis-of-deb-tace-treatment-in-elderly-patients-with-hepatocellular-carcinoma-a-comparative-cohort-study
#9
Qing Yang, Xiaosheng Jin, Fangpeng Ye, Bingru Zheng, Xiangpang Xie, Ya Luo, Zhenjing Shi, Changsheng Shi
The aim of this study was to explore the difference of liver function change, safety profiles and efficacy of drug-eluting bead transarterial chemoembolization (DEBTACE) therapy between elderly and middle-aged hepatocellular carcinoma (HCC) patients. 91 HCC patients were enrolled in this prospective cohort study. They were treated by DEB-TACE therapy and divided into elderly group (age >= 65 years, n=30) and middle-aged group (age < 65 years, n=61), liver function, safety profiles and treatment response were recorded...
May 8, 2018: Oncology Research
https://www.readbyqxmd.com/read/29739274/comprehensive-analysis-of-factors-affecting-clinical-response-and-short-term-survival-to-drug-eluting-bead-transarterial-chemoembolization-for-treatment-in-patients-with-liver-cancer
#10
Xia Wu, Ran Chen, Weiliang Zheng, Hongjie Hu
This study aimed to investigate the clinical response and short-term survival and further explore the comprehensive factors for predicting clinical outcomes in patients with liver cancer treated by drug-eluting beads transarterial chemoembolization . Forty-nine patients with liver cancer who received drug-eluting beads transarterial chemoembolization treatment were consecutively enrolled in this cohort study. Demographic features, medical histories, clinicopathological properties, biochemical indexes, previous treatments, and chemoembolization reagents were recorded...
January 1, 2018: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/29729113/multicenter-study-of-staging-and-therapeutic-predictors-of-hepatocellular-carcinoma-recurrence-following-transplantation
#11
Theodore H Welling, Kevin Eddinger, Kristen Carrier, Danting Zhu, Tyler Kleaveland, Derek E Moore, Douglas E Schaubel, Peter L Abt
Orthotopic liver transplantation (OLT) and resection are effective treatments for hepatocellular carcinoma (HCC). However, optimizing OLT and limiting HCC recurrence remains a vexing problem. New HCC MELD and allocation algorithms provide greater observation of HCC patients, many while receiving local-regional treatments. Potential benefits of local-regional treatment for limiting HCC recurrence post-OLT remain incompletely understood. Therefore we aimed to define HCC specific prognostic factors affecting recurrence in a contemporary, multi-center cohort of HCC patients undergoing OLT and specifically whether local-regional therapies limited recurrence...
May 5, 2018: Liver Transplantation
https://www.readbyqxmd.com/read/29724521/chemoembolization-of-hepatocellular-carcinoma-with-drug-eluting-polyethylene-glycol-embolic-agents-single-center-retrospective-analysis-in-302-patients
#12
Filipe Veloso Gomes, João A Oliveira, Mariana Tomé Correia, Nuno Vasco Costa, João Abrantes, Daniel Torres, Pedro Pereira, Ana Isabel Ferreira, José Hugo Luz, Erik Spaepen, Tiago Bilhim, Élia Coimbra
PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization with polyethylene glycol (PEG) drug-eluting embolic agents in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A single-center retrospective study of 302 patients (258 men; 85.4%) with HCC treated during a 20-month period was conducted. The mean patient age was 66 years ± 10; 142 (47%) had Barcelona Clinic Liver Cancer stage A disease and 134 had (44.4%) stage B disease; 174 (57...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29715141/liver-dominant-breast-cancer-metastasis-a-comparative-outcomes-study-of-chemoembolization-versus-radioembolization
#13
Jodie Chang, Resmi Charalel, Christopher Noda, Raja Ramaswamy, Seung Kwon Kim, Michael Darcy, Gretchen Foltz, Olaguoke Akinwande
AIM: To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS: A retrospective review was carried out of all patients who underwent TACE or TARE for liver-dominant breast cancer metastases between January 2006 and March 2016 at an academic medical center in the United States. RESULTS: Seventeen patients in the TACE group and 30 patients in the TARE group received 32 TACE and 49 TARE treatments, respectively...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29707868/transarterial-chemoembolization-in-children-to-treat-unresectable-hepatocellular-carcinoma
#14
Krista E Weiss, Daniel Y Sze, Arun A Rangaswami, Carlos O Esquivel, Waldo Concepcion, Edward A Lebowitz, Nishita Kothary, Matthew P Lungren
Children with unresectable HCC have a dismal prognosis and few approved treatment options. TACE is an effective treatment option for adults with HCC, but experience in children is very limited. Retrospective analysis was performed of 8 patients aged 4-17 years (4 male, mean 12.5 years) who underwent TACE for unresectable HCC. Response to TACE was evaluated by change in AFP, RECIST and tumor volume, PRETEXT, and transplantation eligibility by UCSF and Milan criteria. Post-procedure mean follow-up was 8.2 years...
April 29, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29702018/percutaneous-ablation-for-hepatocellular-carcinoma
#15
Jeffrey L Weinstein, Muneeb Ahmed
OBJECTIVE: The purpose of this article is to discuss the use, comparative efficacy, and general technical considerations of percutaneous ablation, alone or in combination with other therapies, for the treatment of hepatocellular carcinoma (HCC). CONCLUSION: Percutaneous ablation is a mainstay treatment for early-stage HCC, offering survival comparable to that of surgical resection for small lesions. It can act as a primary curative therapy or bridge therapy for patients waiting to undergo liver transplant...
April 27, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29686471/analysis-of-aggressiveness-factors-in-hepatocellular-carcinoma-patients-undergoing-transarterial-chemoembolization
#16
Yossi Ventura, Brian I Carr, Issac Kori, Vito Guerra, Oren Shibolet
AIM: To investigate novel predictors of survival in hepatocellular carcinoma (HCC) patients following transarterial chemoembolization (TACE). METHODS: One hundred sixty seven patients with un-resectable HCC were retrospectively analyzed to identify factors that might contribute to their HCC biology and aggressiveness. We correlated routine laboratory results (total bilirubin, AST, ALKP, GGTP, albumin etc .) to maximum tumor diameter, number of tumor nodules, portal vein thrombosis and blood alpha-fetoprotein levels...
April 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29685527/survival-of-patients-with-non-resectable-chemotherapy-resistant-colorectal-cancer-liver-metastases-undergoing-conventional-lipiodol-based-transarterial-chemoembolization-ctace-palliatively-versus-neoadjuvantly-prior-to-percutaneous-thermal-ablation
#17
Thomas J Vogl, Maximilian Lahrsow, Moritz H Albrecht, Renate Hammerstingl, Zachary M Thompson, Tatjana Gruber-Rouh
PURPOSE: To determine overall (OS) and progression-free survival (PFS) for cTACE alone and in combination with percutaneous thermal ablation in patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases (CRLM). MATERIAL AND METHODS: The study included 452 patients undergoing 2654 repetitive cTACE treatments of CRLM. 233 patients were treated palliatively using only cTACE, whereas 219 patients were treated with cTACE in a neoadjuvant intend with subsequent thermal ablation (either microwave ablation or laser-induced thermotherapy)...
May 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29671661/combination-therapy-of-tace-and-ct-guided-partial-hepatic-segment-ablation-for-liver-cancer
#18
Yang Wang, Liang Ma, Shoupeng Sheng, Zhuhui Yuan, Jiasheng Zheng, Wei Li
AIM: This study aimed to investigate the safety and efficacy of combination therapy of transcatheter arterial chemoembolization (TACE) and CT-guided percutaneous partial hepatic segment ablation. MATERIAL AND METHODS: Liver cancer patients undergoing TACE plus partial segment ablation from 2012 to 2016 were retrospectively analyzed. Patient characteristics were collected. TACE was performed for all patients before ablation. After ablation, CT imagings were used to evaluate treatment and follow-up...
April 19, 2018: Minimally Invasive Therapy & Allied Technologies: MITAT
https://www.readbyqxmd.com/read/29670363/long-term-survival-with-transarterial-chemoembolization-and-radioembolization-in-a-patient-with-cancers-of-unknown-primary
#19
Gokmen Aktas, Tulay Kus, Taylan Metin, Selim Kervancioglu, Umut Elboga
Cancers of unknown primary (CUP) are histologically proven metastatic malignant tumors without an identified primary site before treatment. The common characteristics are early dissemination, lower response to chemotherapy and poor prognosis with short life expectancy. Treatment was directed according to the presence of localized or disseminated disease. The most frequent site of metastasis is the liver, which is a suitable target organ for arterial-directed therapies. We report a case of 53-year-old woman who was diagnosed with CUP and suspected with intracellular cholangiocellular carcinoma (ICC), presented with a very large, unresectable, chemotherapy-refractory hepatic mass and treated with transarterial chemoembolization and transarterial radioembolization and surprisingly followed for 48 months with minimally progressive and stable disease...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29662837/patient-selection-for-transarterial-chemoembolization-in-hepatocellular-carcinoma-importance-of-benefit-risk-assessment
#20
REVIEW
Fabio Piscaglia, Sadahisa Ogasawara
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellular carcinoma (HCC) accounting for most primary liver cancers and most commonly arising from a history of advanced chronic liver disease. Among the available therapies, transarterial chemoembolization (TACE) is the most widely utilized and is considered the first-line treatment recommended for patients staged as intermediate HCC (Barcelona Clinic Liver Cancer stage B). If applied correctly, TACE can produce survival benefits without adversely affecting hepatic functional reserve...
March 2018: Liver Cancer
keyword
keyword
72036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"